Matinas BioPharma (MTNB) Begins ENHANCE-IT Study of MAT9001 Against Vascepa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. ALAR
4. PRYMY
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. CCHGY
10. PRY:IM

Go back to Matinas BioPharma (MTNB) Begins ENHANCE-IT Study of MAT9001 Against Vascepa

Matinas BioPharma (MTNB) Misses Q4 EPS by 1c

March 9, 2020 6:33 AM EDT

Matinas BioPharma (NYSE: MTNB) reported Q4 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03).

2019 was a year of significant operational progress for Matinas and we are very excited to have advanced both of our clinical stage assets, MAT9001 and MAT2203, into key efficacy trials early in 2020, commented Jerome D. Jabbour, Chief Executive Officer of Matinas. ENHANCE-IT represents a significant... More